Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma:in vitroand phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition-Reference-Cited by-同舟云学术

Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma:in vitroand phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition

Published:2012-02-13 Issue:8 Volume:53 Page:1501-1508
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Dummer Reinhard,Beyer Marc,Hymes Kenneth,Epping Mirjam T.,Bernards Rene,Steinhoff Matthias,Sterry Wolfram,Kerl Helmut,Heath Karl,Ahern Janet D.,Hardwick James S.,Garcia-Vargas Jose,Baumann Katrin,Rizvi Syed,Frankel Stanley R.,Whittaker Sean J.,Assaf Chalid

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2012.656625

Reference51 articles.

1. WHO-EORTC classification for cutaneous lymphomas

2. Primary cutaneous lymphomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

3. Bexarotene: a clinical review

4. The promise of retinoids to fight against cancer

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat;Heliyon;2024-06

2. Exploring the nexus of nuclear receptors in hematological malignancies;Cellular and Molecular Life Sciences;2024-02-09

3. What’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus;American Journal of Clinical Dermatology;2023-11-16

4. Cutaneous Lymphoma and Antibody-Directed Therapies;Antibodies;2023-03-03

5. Identification of a novel candidate target molecule progesterone receptor as a candidate molecule for combination with HDAC inhibitor therapy by kinome analysis;Electrophoresis Letters;2023